Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

D0600000

Deslanoside

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Deacetyllanatoside C, Desacetyllanatoside C

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C47H74O19
Número de CAS:
Peso molecular:
943.08
Número MDL:
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

deslanoside

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

O1CC(=CC1=O)[C@@H]2[C@@]3([C@@]([C@H]4[C@@H]([C@@]5([C@@H](C[C@H](CC5)O[C@@H]6O[C@@H]([C@H]([C@H](C6)O)O[C@@H]7O[C@@H]([C@H]([C@H](C7)O)O[C@@H]8O[C@@H]([C@H]([C@H](C8)O)O[C@@H]9O[C@@H]([C@H]([C@@H]([C@H]9O)O)O)CO)C)C)C)CC4)C)C[C@H]3O)(CC2)O)C

InChI

1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1

Clave InChI

OBATZBGFDSVCJD-LALPQLPRSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Deslanoside EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Pictogramas

Skull and crossbonesHealth hazard

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - STOT RE 2

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Topochemical examinations of the lungs of the rat after combined administration of serpasil and deslanatoside. I. Histochemical examinations.
E A Jedrzejewska
Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 42, 133-138 (1987-01-01)
A Fronczak et al.
Polish journal of pharmacology and pharmacy, 41(6), 597-609 (1989-11-01)
4'-epidoxorubicin (4'-epiDXR) was compared with doxorubicin (DXR) for myocardial effects in rabbits. Histologically, both drugs when given for six weeks induced a high incidence of diffused myocardial damage. The myocardial damage was less evident in rabbits treated with 4'-epiDXR than
E J Eichhorn et al.
Circulation, 85(6), 2132-2139 (1992-06-01)
Although changes in contractility are often accompanied by changes in relaxation, a mathematical model of ventricular coupling has not been described. A model we examined suggests a hyperbolic relation between measurements of contraction and relaxation. We thus tested the hypothesis
[Pharmacological cardioversion of paroxysmal atrial fibrillation: 3 methods compared].
D Tsialtas et al.
La Clinica terapeutica, 122(2), 93-98 (1987-07-31)
Wayne L Miller et al.
European journal of heart failure, 4(1), 63-72 (2002-01-29)
Digitalis has a long history in the treatment of heart failure but its effects on cardiac hemodynamics and neurohormonal modulation are not well characterized. The purpose of this study was to evaluate the relationship between atrial natriuretic peptide (ANP) and

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico